论文部分内容阅读
目的探讨微小核糖核酸-25(miRNA-25)对于胃癌患者的危险性判断及预后评估的临床意义。方法纳入2010年2月—2011年2月我院收治的72例胃癌的临床资料,并进行电话随访。根据患者预后分为未转移组和转移组,通过组间单因素比较及多因素Logistic回归分析等方法评价各因素与胃癌预后的相关性。结果本研究共纳入69例胃癌,在年龄、性别、吸烟史、miRNA-25、CA19-9方面转移组与未转移组比较,差异均有统计学意义。经Logistic回归分析结果显示年龄[OR=1.04,95%可信区间(CI):1.01～1.08,P<0.01]、男性所占比例(OR=1.05,95%CI:1.02～1.09,P<0.01)、吸烟史(OR=1.33,95%CI:1.27～1.48,P<0.01)、miRNA-25(OR=1.14,95%CI:1.09～1.22,P<0.01)、CA19-9(OR=1.29,95%CI:1.13～1.44,P<0.01)与患者预后存在显著相关性。通过工作特征(ROC)曲线检验miRNA-25的预测效能,计算曲线下面积为0.855(95%CI:0.818～0.892,P<0.01)。结论 miRNA-25可作为胃癌的独立诊断因素,将该指标纳入胃癌的诊断评测体系可进一步增强评估该病风险和预后的能力。
Objective To investigate the clinical significance of miRNA-25 (miRNA-25) in determining the risk of patients with gastric cancer and assessing prognosis. Methods The clinical data of 72 cases of gastric cancer admitted to our hospital from February 2010 to February 2011 were included and followed up by telephone. According to the prognosis of patients, they were divided into non-metastasis group and metastasis group, and the correlation between each factor and prognosis of gastric cancer was evaluated by single factor comparison and multivariate Logistic regression analysis. Results A total of 69 cases of gastric cancer were enrolled in this study. There were significant differences in age, gender, smoking history, miRNA-25, CA19-9 between metastatic group and non-metastatic group. Logistic regression analysis showed that age (OR = 1.04, 95% CI: 1.02 ~ 1.09, P <0.01) ), Smoking history (OR = 1.33, 95% CI: 1.27-1.48, P <0.01) , 95% CI: 1.13-1.44, P <0.01) had a significant correlation with the prognosis of patients. The predicted efficacy of miRNA-25 was tested by ROC curves, and the area under the calculated curve was 0.855 (95% CI: 0.818-0.892, P <0.01). Conclusion miRNA-25 can be used as an independent diagnostic factor for gastric cancer. The inclusion of this indicator in the diagnostic evaluation system for gastric cancer further enhances the ability to assess the risk and prognosis of gastric cancer.